With the prostate-specific antigen (PSA) test now considered a less-than-reliable screen for prostate cancer, a worldwide search is underway to find an inexpensive, minimally invasive, and more effective tool to replace what was once considered the gold standard biomarker.
Now, an international team of researchers is reporting the creation of a multi-gene liquid biopsy biomarker or signature with a greater than 90 percent accuracy to diagnose and monitor disease status during treatment.
“There is a significant unmet need for the development of a new biomarker in this space,” said Mark Kidd, PhD, Laboratory and Scientific Director with Wren Laboratories who presented the findings during the American Association for Cancer Research (AACR) Virtual Annual Meeting II, held online June 22-24.
